HTR1A
ENSG00000178394
Target class
GPCR
Chromosome
5
Approved drugs
13
Clinical candidates (approved and in development)
29
- Approved drugs
- 13
- Clinical candidates (approved and in development)
- 29
- Chemical probe available
- Yes
- Other names
- 5-HT1A
- Target name
- HTR1A
- Gene name
- 5-hydroxytryptamine receptor 1A
- Gene symbol
- HTR1A
- Protein name
- 5-hydroxytryptamine receptor 1A (5-HT-1A) (5-HT1A) (G-21) (Serotonin receptor 1A)
- ADRB2RL1
- ADRBRL1
- Gene biotype
- Protein coding
- Gene family
- 5-hydroxytryptamine receptors, G protein-coupled
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 4
- Highest tissue expression
- 2.59
- Tissue specificity (Gini)
- 0.907
- Tissue specificity (tau)
- 0.955
- KEGG gene identifiers
- hsa:3350
- Reactome pathways
- R-HSA-390666
- Protein interaction confidence
- 0.799306
- Protein interaction partners
- 36
- End position
- 63962507
- Start position
- 63957874
- Chromosome
- 5
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein . Cell projection, dendrite .
- PubMed 22957663
- PubMed 26365466
- PubMed 3041227
- PubMed 3138543
- PubMed 8393041
- Tissue specificity (tau)
- 0.954761
- Expression inequality (Gini)
- 0.906818
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 2.59
- Brain - Cortex
- 2.24
- Brain - Anterior cingulate cortex (BA24)
- 1.31
- Brain - Hippocampus
- 1.1
- Brain - Hypothalamus
- 0.45
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)2.59
- Brain - Cortex2.24
- Brain - Anterior cingulate cortex (BA24)1.31
- Brain - Hippocampus1.1
- Brain - Hypothalamus0.45
- Brain - Amygdala0.41
- Brain - Caudate (basal ganglia)0.17
- Ovary0.17
- Brain - Nucleus accumbens (basal ganglia)0.12
- Brain - Spinal cord (cervical c-1)0.06
- Testis0.06
- Brain - Substantia nigra0.05
- Brain - Putamen (basal ganglia)0.04
- Pituitary0.03
- Spleen0
- Thyroid0
- Prostate0
- Skin - Sun Exposed (Lower leg)0
- Colon - Transverse0
- Esophagus - Mucosa0
- Heart - Left Ventricle0
- Kidney - Medulla0
- Minor Salivary Gland0
- Artery - Tibial0
- Lung0
And 29 more, listed on the interactive page.
- GO:0007186
- GO:0007198
- GO:0008284
Cellular components
- GO:0005886
- GO:0001586
- GO:0004993
- GO:0005515
- GO:0090722
decreased aggression
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased aggression
- nervous system
- endocrine
- cardiovascular
PubMed 28216264decreased sleep
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased sleep
- nervous system
- endocrine
- cardiovascular
PubMed 28216264decreased memory
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased memory
- nervous system
- endocrine
- cardiovascular
PubMed 28216264decreased anxiety
- Inhibition/Decrease/Downregulation: acute
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased anxiety
- nervous system
- endocrine
- cardiovascular
PubMed 28216264decreased body temperature
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased body temperature
- nervous system
- endocrine
- cardiovascular
PubMed 28216264paresthesia
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: paresthesia
- nervous system
- endocrine
- cardiovascular
PubMed 28216264decreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood pressure
- nervous system
- endocrine
- cardiovascular
PubMed 28216264stereotypy
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: stereotypy
- nervous system
- endocrine
- cardiovascular
PubMed 28216264increased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased heart rate
- nervous system
- endocrine
- cardiovascular
PubMed 28216264decreased/increased locomotor activity
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased/increased locomotor activity
- nervous system
- endocrine
- cardiovascular
PubMed 28216264increased memory
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased memory
- nervous system
- endocrine
- cardiovascular
PubMed 28216264dizziness
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: dizziness
- nervous system
- endocrine
- cardiovascular
PubMed 28216264visual disturbances
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: visual disturbances
- nervous system
- endocrine
- cardiovascular
PubMed 28216264growth hormone secretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: growth hormone secretion
- nervous system
- endocrine
- cardiovascular
PubMed 28216264increased/decreased pupil diameter
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased/decreased pupil diameter
- nervous system
- endocrine
- cardiovascular
PubMed 28216264cortisol secretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: cortisol secretion
- nervous system
- endocrine
- cardiovascular
PubMed 28216264decreased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased pain
- nervous system
- endocrine
- cardiovascular
PubMed 28216264increased adrenocorticotropic hormone
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased adrenocorticotropic hormone
- nervous system
- endocrine
- cardiovascular
PubMed 28216264increased/decreased sleep
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased/decreased sleep
- nervous system
- endocrine
- cardiovascular
PubMed 28216264increased locomotor activity
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased locomotor activity
- nervous system
- endocrine
- cardiovascular
PubMed 28216264
cortisol secretion
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: cortisol secretion
- central nervous system
- endocrine
PubMed 23197038growth hormone secretion
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: growth hormone secretion
- central nervous system
- endocrine
PubMed 23197038decreased body temperature
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: decreased body temperature
- central nervous system
- endocrine
PubMed 23197038reduced REM sleep
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: reduced REM sleep
- central nervous system
- endocrine
PubMed 23197038increased adrenocorticotropic hormone
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: increased adrenocorticotropic hormone
- central nervous system
- endocrine
PubMed 23197038potentially anxiogenic
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: potentially anxiogenic
- central nervous system
- endocrine
PubMed 23197038
Related records
Trials (818)
- "Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program"
- [18F]-F13640 as a New Brain Radiopharmaceutical
- 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
- 12- Week Open Label Treatment of Refractory Bipolar Depression
- 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
- 18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
- A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder
- A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
- A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets
- A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
- A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard
- A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia
- A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
- A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication
- A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
- A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia
- A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging
- A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia
- A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.
- A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
Drugs (38)
- Adoprazine Serotonin 1a (5-HT1a) receptor agonist
- Alverine Serotonin 1a (5-HT1a) receptor antagonist
- Amisulpride Serotonin (5-HT) receptor antagonist
- Aripiprazole Serotonin 1a (5-HT1a) receptor partial agonist
- Aripiprazole lauroxil Serotonin 1a (5-HT1a) receptor partial agonist
- Befiradol Serotonin 1a (5-HT1a) receptor agonist
- Bifeprunox Serotonin 1a (5-HT1a) receptor partial agonist
- Brexpiprazole Serotonin 1a (5-HT1a) receptor partial agonist
- Buspirone Serotonin 1a (5-HT1a) receptor partial agonist
- Buspirone hydrochloride Serotonin 1a (5-HT1a) receptor partial agonist
- Dexfenfluramine Serotonin (5-HT) receptor agonist
- Dexfenfluramine hydrochloride Serotonin (5-HT) receptor agonist
- DU 125530 Serotonin 1a (5-HT1a) receptor antagonist
- Ergoloid Serotonin 1a (5-HT1a) receptor agonist
- Ergoloid mesylates Serotonin 1a (5-HT1a) receptor agonist
- Gepirone Serotonin 1a (5-HT1a) receptor agonist
- Gepirone hydrochloride Serotonin 1a (5-HT1a) receptor agonist
- GSK163090 Serotonin 1a (5-HT1a) receptor antagonist
- Lecozotan Serotonin 1a (5-HT1a) receptor antagonist
- Lecozotan hydrochloride Serotonin 1a (5-HT1a) receptor antagonist